From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Best clinical response
All patients
(N = 46), n (%)
CRb
2 (4)
PR
SD
13 (28)
PD
26 (57)
Unknownc
3 (7)